[hu3]

Nice.

This tells me that research on the drug is old and that increases security on its use.

[epistasis]

GLP-1 is a drug target, not a drug. It's actually a hormone.

There are many drugs that have been developed since then, and each approval seems to have slightly better drug properties.

The age of research on a drug is not very indicative of safety, either. Rather, broad study and time are far better. I'd take five years of clinical trials on hundreds of thousands of people over 5000 years old research on hundreds of people.

[stavros]

It's so old, the patent is nearing expiration.

[scheme271]

The first generation of GLP-1 agonists are out of patent protection. Teva is producing a generic liraglutide (aka Victoza / Saxenda). Ozempic (semiglutide) and Mounjaro (tirzepatide) have protection until after 2031 in the US, I think it's less in other countries.

[wombatpm]

That’s usually the case for new classes of drugs.

[refurb]

Not necessarily. If it just sits on a shelf, there is no new data on it's use in humans.